PharmaLeaders.com

News. Resources. Community.

  • Features
  • Channels
    • Biotech Channel
    • Clinical Channel
    • CME Channel
    • Compliance Channel
    • Device Channel
    • HIMSS Channel
    • Marketing Channel
    • Pharma Channel
    • R&D Channel
    • Telehealth Channel
    • Training Channel
  • Events
  • On Demand
  • White Papers
  • Vendors
    • Biotech Vendors
    • Clinical Vendors
    • CME Vendors
    • Compliance Vendors
    • Device Vendors
    • Marketing Vendors
    • Pharma Vendors
    • R&D Vendors
    • Training Vendors
  • Contributors

Moving Beyond the Hype Curve? Pharma Leverages Big Data Expertise Across the Product Life Cycle

11/20/2018 by Andrea

Author: Jim Walker, Contributing Editor, PharmaLeaders

At the recent EyeForPharma “Marketing & Customer Experience” session in Philadelphia, it was not surprising to learn that many Big Pharma companies have been embracing Big Data solutions. In fact, data has been at the heart of pharma R&D for decades. Recently, as customer data sources have exploded, many firms are staffing up their data teams to tackle the other end of the pipeline – namely applying machine learning and data algorithms to address complex commercial challenges.

Taking a deep dive into Big Data, Steve Wong and Zheng Yang from Boehringer Ingelheim each presented a wide range of cases where BI is harnessing data to do everything from optimize product shipping and logistics to analyzing mobile data that measures the prevalence of coughing in a target population.

Interestingly, the latest Gartner tracking has found we are at the peak of the AI and Deep Learning Hype Cycle.

Source: Gartner 2018

If it feels like this Big Data story never gets old, it might be because, according to Gartner, that we have been at a Hype Peak for Machine Learning and Deep Learning for the past four years!

So where do we go from here? If the adoption curve holds true, the hype will finally start to die down and there might even be a backlash. Eventually though, in the 2020s we should see countless applications emerge for AI and machine learning across all aspects of healthcare, which will impact not just R&D, but commercialization and clinical practice as well. In the meantime, teams at BI and elsewhere will continue to leverage their deep expertise across a range of groundbreaking commercial challenges.

 

Filed Under: Biotech Posts, Channels, Clinical Channel Posts, CME Channel Posts, Compliance Channel Posts, Device Channel Posts, Features, HIMSS Channel Posts, Industry News, Marketing Channel Posts, Pharma Channel Posts, Research and Development Channel Posts Tagged With: big data, business intelligence, eyeforpharma, marketing, technology

  • Facebook
  • LinkedIn
  • Twitter

Choose Your Channel

Receive event announcements and special reports directly in your inbox.
  • This field is for validation purposes and should be left unchanged.

  • About Us
  • Sponsorship
  • Join Our Team
  • Contact Us

Copyright © 2023 PharmaLeaders.com. All rights reserved.